New hope for AML patients: targeted combo challenges standard chemo
NCT ID NCT07425808
First seen Feb 23, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This study compares a new three-drug combination (gilteritinib, azacitidine, and venetoclax) to standard intensive chemotherapy for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 participants aged 18 to 75 will be randomly assigned to one of the two treatments. The goal is to see if the new combo leads to better remission rates and longer survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.